HOME >> MEDICINE >> NEWS
NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

dicine and director of the AIDS unit; Dr. David Wohl, research fellow in medicine; and research clinician Janet Groves.

Nationwide, researchers found 63 "disease progression events" -- including AIDS-related illnesses and deaths among patients receiving a combination of ZDV and 3TC, Eron said. Among patients receiving those two drugs and indinavir, they found only 33 such events.

"There were 18 deaths in the double-therapy arm of the study vs. eight deaths in the triple- therapy arm," he said. "No major differences were found in either safety or toxicity between the two treatments, and study medications were well-tolerated."

Indinavir, a protease inhibitor, works by preventing protease enzymes from cutting up proteins needed to form viruses, Eron explained. The envelope, or outer coating, of the virus still develops, but the core cannot, and therefore the resulting virus is not infectious.

Drugs such as ZDV and 3TC work by inhibiting an enzyme called reverse transcriptase. That enzyme enables the virus' genetic material, or RNA, to convert human genetic material known as DNA into more virus.

The Food and Drug Administration approved use of the combined ZDV and 3TC in November 1995, in part because of a national study Eron led and published in the New England Journal of Medicine. Indinavir has been approved for about a year.

"The people who should be thanked and congratulated for this study and others like it are the people who participated in the trials," Eron said. "They not only have done something that will improve their own care, but they have volunteered to do something that will clearly improve the care of many patients afterwards.

"Treatment with the triple-drug therapy is not easy because of the large number of pills patients have to take and the commitment they have to make to stick to the therapy," he said. "They are the real heroes here."

Glaxo-Wellcome Inc. of Research Triangle Park
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-2091
University of North Carolina at Chapel Hill
25-Feb-1997


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
(Date:11/24/2014)... November 24, 2014 The typical American ... the wrong ingredients. Consistently consuming a diet high in ... stores of excess fat that typically accumulate around the ... rearing its ugly head in the form of love ... dieters make the decision to rid themselves of the ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading ... Tier recognition in the 2015 Edition of U.S. News-Best Lawyers ... a unique combination of quality law practice and breadth of ... honor and especially grateful to our clients whose continued support ... possible,” said Jeff S. Korek, senior partner at Gersowitz ...
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... 23, 2014 The report, “Market ... to 2020 - Asia-Pacific” provides quantitative analysis of ... segments: minimally invasive body contouring devices, non-invasive body ... includes market size data by revenue and volume ... countries: China, Japan, South Korea, Australia and India. ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... tests, has appointed Juliet Cunningham as Vice ... will be responsible for driving communications with the investment ... a series of changes to increase shareholder value, it ... investors," said Namal Nawana, Chief Executive Officer. "We are ...
(Date:11/21/2014)... Nov. 21, 2014 In September 2014, the ... carried out a new product development plan that started ... "limited edition" lab coat , aptly named "Vera ... surgery in the world. The new women,s designer lab ... with a sleek envelope collar, vertical princess and high ...
(Date:11/21/2014)... Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... and research markets in the United States ... purchase agreement to acquire 100% of QCR & Trio ... based distribution organization. The transaction closed on November 17, ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
Cached News: